Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G9YH
|
|||
| Former ID |
DAP000046
|
|||
| Drug Name |
Amsacrine
|
|||
| Synonyms |
Acridinylanisidide; Amecrin; Amekrin; Amsacrina; Amsacrinum; Amsidine; Amsidyl; Amsine; Lamasine; MAMSA; NAMSA; Acridinyl Anisidide; SN 21429; SN11841; AMSA P-D; Acridinyl anisidide (TN); Amsacrina [INN-Spanish]; Amsacrinum [INN-Latin]; Amsidyl (TN); Cain's Acridine; M-AMSA; Meta-AMSA; Meta-Amsacrine; SN-11841; Amsacrine (USAN/INN); Amsacrine [USAN:BAN:INN]; M-AMSA (TN); N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide; N-(4-(9-Acridinylamino)-3-methoxyphenyl)methanesulfonamide; N-[4-(9-Acridinylamino)-3-methoxy-phenyl]methanesulfonamide; N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide; N-[4-(acridin-9-ylmethyl)-3-methoxyphenyl]methanesulfonamide; N-(4-(Acridin-9-ylamino)-3-methoxyphenyl)methanesulfonamide; N-[4-(Acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide; N-[4-(acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide; 4'-(9-Acridinylamino)-3'-methoxymethanesulfonanilide; 4'-(9-Acridinylamino)methanesulfon-m-anisidide; 4'-(9-Acridinylamino)methanesulfon-meta-anisidide; 4'-(9-Acridinylamino)methanesulphon-m-anisidide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute lymphoblastic leukaemia [ICD-11: 2A85; ICD-10: C85.1, C88.7] | Approved | [1] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Travenol Laboratories Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H19N3O3S
|
|||
| Canonical SMILES |
COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42
|
|||
| InChI |
1S/C21H19N3O3S/c1-27-20-13-14(24-28(2,25)26)11-12-19(20)23-21-15-7-3-5-9-17(15)22-18-10-6-4-8-16(18)21/h3-13,24H,1-2H3,(H,22,23)
|
|||
| InChIKey |
XCPGHVQEEXUHNC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 51264-14-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
4711, 137181, 597748, 5128698, 7849380, 7978704, 8137254, 8151483, 11110803, 11406388, 11447254, 11533500, 12013305, 14927834, 29221358, 46507539, 47440375, 48110554, 48415564, 48422855, 49815687, 49855467, 50110958, 53789073, 57321186, 78687979, 90341308, 99453443, 103166066, 103919715, 103925608, 104299838, 118043462, 121379628, 124633410, 124879323, 124879324, 125824264, 126659536, 126687025, 127318462, 127318463, 127318464, 127318465, 127318466, 127318467, 127318468, 127318469, 127318470, 127318471
|
|||
| ChEBI ID |
CHEBI:2687
|
|||
| ADReCS Drug ID | BADD_D00137 | |||
| SuperDrug ATC ID |
L01XX01
|
|||
| SuperDrug CAS ID |
cas=051264143
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA topoisomerase II (TOP2) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Identification of FDA-approved drugs and bioactives that protect hair cells in the zebrafish (Danio rerio) lateral line and mouse (Mus musculus) ut... J Assoc Res Otolaryngol. 2009 Jun;10(2):191-203. | |||
| REF 2 | Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Anticancer Drug Des. 2000 Dec;15(6):413-21. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.